Want to see ETON full AI Analyst Report?
ETON Stock Chart & Stats
$42.59
$1.05(2.47%)
At close: 4:00 PM EDT
$42.59
$1.05(2.47%)
Day’s Range― - ―
52-Week Range$13.99 - $50.18
Previous CloseN/A
Volume7.82K
Average Volume (3M)471.28K
Market Cap
$1.27B
Enterprise Value$790.19
Total Cash (Recent Filing)$19.66M
Total Debt (Recent Filing)$12.25M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 13, 2026EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding27,392,359
10 Day Avg. Volume601,246
30 Day Avg. Volume471,279
Financial Highlights & Ratios
PEG Ratio-7.46
Price to Book (P/B)17.40
Price to Sales (P/S)5.69
P/FCF Ratio44.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$54.75Price Target Upside28.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.86
Revenue Forecast (FY)$115.47M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & ScalingEton has demonstrated durable top-line momentum with multi-year revenue scaling to ~$86.9M TTM and a raised FY2026 revenue guide (> $120M). This sustained commercial growth supports investment in distribution, payer access, and operational scale that underpin long-term market expansion.
Margin Expansion & Profitability ProgressHigh and improving adjusted gross margins (mid-50% reported, 67% adjusted in Q1 with a 70%+ target) and rising adjusted EBITDA (24% in Q1; >30% guide for 2026) indicate durable unit economics in orphan and pediatric specialties, supporting long-term cash generation as scale continues.
Portfolio Expansion & PipelineRecent licensing (ASN-001), KHINDIVI label expansion pursuits, and IMPAVIDO U.S. rights materially expand Eton’s orphan/pediatric franchise. Late-stage assets plus patent protection (ASN-001 through 2044) diversify revenue levers and create durable upside from both marketed and near-term regulatory milestones.
Bears Say
Ongoing GAAP LossesDespite improving adjusted profitability, Eton remains GAAP loss-making and shows negative returns on equity. Continued dependence on future launches and approvals to deliver GAAP profitability increases execution risk and limits durable free cash available for dividends or large reinvestments.
Cash Flow Variability & Tight Near-Term LiquidityOperating and free cash flow are positive but volatile, with OCF stepping down materially versus 2025. Coupled with a $14M acquisition payment and a modest ~$19.7M cash balance, this variability constrains flexibility for R&D, launches, or bolt-on deals until consistent cash conversion is re-established.
Reimbursement & Launch Execution RiskHEMANGEOL faces structural reimbursement and mix risk: a large share of patients may generate little net revenue and transfers to a single specialty pharmacy complicate rollout. Such durable payer and mix uncertainty can materially reduce realized pricing and the long-term revenue potential of new launches.
Eton Pharmaceuticals News
ETON FAQ
What was Eton Pharmaceuticals’s price range in the past 12 months?
Eton Pharmaceuticals lowest stock price was $13.98 and its highest was $50.18 in the past 12 months.
What is Eton Pharmaceuticals’s market cap?
Eton Pharmaceuticals’s market cap is $1.27B.
When is Eton Pharmaceuticals’s upcoming earnings report date?
Eton Pharmaceuticals’s upcoming earnings report date is Aug 13, 2026 which is in 8 days.
How were Eton Pharmaceuticals’s earnings last quarter?
Eton Pharmaceuticals released its earnings results on May 14, 2026. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.113 by $0.027.
Is Eton Pharmaceuticals overvalued?
According to Wall Street analysts Eton Pharmaceuticals’s price is currently Undervalued.
Does Eton Pharmaceuticals pay dividends?
Eton Pharmaceuticals does not currently pay dividends.
What is Eton Pharmaceuticals’s EPS estimate?
Eton Pharmaceuticals’s EPS estimate is 0.16.
How many shares outstanding does Eton Pharmaceuticals have?
Eton Pharmaceuticals has 27,392,359 shares outstanding.
What happened to Eton Pharmaceuticals’s price movement after its last earnings report?
Eton Pharmaceuticals reported an EPS of $0.14 in its last earnings report, beating expectations of $0.113. Following the earnings report the stock price went up 1.001%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals?
Currently, no hedge funds are holding shares in ETON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eton Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.75 (28.55% Upside)
$54.75 (28.55% Upside)
Blogger Sentiment
Neutral
ETON Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 75.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
177.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.28%
Trailing 12-Months
Company Description
Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. (ETON) is a U.S.-based specialty pharmaceutical company focused on developing, acquiring, and commercializing prescription products that address underserved or orphan disease markets. The company’s portfolio centers on pediatric and specialty-care medicines, including liquid/oral formulations and other dosage forms intended to improve dosing and administration in patients with specific clinical needs.
ETON Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum: record product revenue (73% YoY), successful launches of DESMODA and HEMANGEOL, raised full‑year guidance (> $120M), improving adjusted EBITDA and multiple high‑value pipeline milestones (INCRELEX label study cleared, ET‑700 and Amglidia progress). Operational scalability was highlighted by relatively modest G&A growth versus revenue growth. Key risks discussed include launch execution and reimbursement uncertainty for HEMANGEOL (large portion of volume potentially near‑zero revenue), modest margin dilution from ex‑U.S. INCRELEX shipments, higher recurring FDA program fees, and near‑term cash impacts from the HEMANGEOL acquisition. On balance, the positive commercial performance, upgraded guidance, and clear pipeline catalysts outweigh the near‑term uncertainties reported.View all ETON earnings summariesETON Stock 12 Month Forecast
Average Price Target
$54.75
▲(28.55% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Cumberland Pharmaceuticals
―
Ownership Overview
14.88% Insiders
6.90% Mutual Funds
2.13% Other Institutional Investors
66.13% Public Companies and
Individual Investors